Skip to main content
. 2008 May 7;14(17):2650–2661. doi: 10.3748/wjg.14.2650

Table 4.

Outcome assessment and reporting for 20 included clinical trials of probiotics for IBS

Outcome
Reference Global response Abdominal pain Bloating/distension Flatulence Stool frequency Mucous Stool consistency Dyspepsia
Maupas[45] R R R R R R
Gade[46] R R R R R
Halpern[47] R A A A A A
Nobaek[48] R R R A R
O’Sullivan[49] R R A R A
Niedzielin[50] R R R A A
Kim[51] R R R R R R
Bausserman[52] A R R A A
Bittner[53] A A A
Kajander[54] R R R R R A A
Kim[55] R R R R R
Niv[56] R R R A
O’Mahony[17] R R R A R
Kim[57] R A A A A
Simren[58] R A A A A A A
Whorwell[35] R R R R A
Enck[59] R R A A A
Gawronska[60] R
Marteau[61] R R A A
Simren[62] R A A
Percent reporting 65% 80% 50% 40% 25% 0 30% 5%

A: Assessed; R: Reported in sufficient detail to allow extraction of data. Bold font indicates that this was the primary outcome identified by the authors for analysis. If author reported no difference between active and placebo groups for a given symptom, but did provide further details, the outcome was classified as assessed only.